Doximity (DOCS)
(Delayed Data from NYSE)
$28.96 USD
+0.93 (3.32%)
Updated May 20, 2024 04:00 PM ET
After-Market: $29.21 +0.25 (0.86%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Doximity (DOCS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$29.67 | $35.00 | $25.00 | 5.85% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Doximity comes to $29.67. The forecasts range from a low of $25.00 to a high of $35.00. The average price target represents an increase of 5.85% from the last closing price of $28.03.
Analyst Price Targets (12)
Broker Rating
Doximity currently has an average brokerage recommendation (ABR) of 2.66 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 2.78 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 17.65% and 5.88% of all recommendations. A month ago, Strong Buy made up 17.65%, while Buy represented 5.88%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 12 | 12 | 11 | 11 | 10 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 2 | 2 | 2 |
ABR | 2.66 | 2.66 | 2.78 | 2.78 | 2.77 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/17/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
5/17/2024 | Needham & Company | Scott Berg | Hold | Hold |
4/2/2024 | Evercore Partners | Elizabeth Anderson | Hold | Hold |
3/15/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Hold | Hold |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
1/7/2024 | BTIG | David M Larsen | Hold | Hold |
11/9/2023 | Raymond James | Brian Peterson | Moderate Buy | Moderate Buy |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Hold |
9/5/2023 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.66 |
ABR (Last week) | 2.66 |
# of Recs in ABR | 17 |
Average Target Price | $29.67 |
LT Growth Rate | 10.30% |
Industry | Medical Services |
Industry Rank by ABR | 140 of 252 |
Current Quarter EPS Est: | 0.21 |